remimazolam

An interesting article titled “Can Remimazolam Be a New Sedative Option for Outpatients Undergoing Ambulatory Oral and Maxillofacial Surgery?” appears in the Journal of Oral and Maxillofacial Surgery written by Zijian Guo and et. al. (Available online 16 September 2022). The article discusses the sedative remimazolam and its possibility to sedate in oral surgery as effectively as midazolam. In the article the authors discuss how patients can receive dental treatment with more comfort using sedation. Midazolam is widely used in oral and maxillofacial surgery but has side effects of increased accumulation and respiratory depression. Remimazolam has similar pharmacological effects to midazolam but has rapid onset, fast metabolism, less potential adverse effects. Remimazolam has a a mean half-life of between 0.5 and two minutes and a terminal half-life in plasma of 37 to 53 minutes.  The authors conducted the first ever … Read more